The Future of Smallpox Vaccination: is MVA the key?
AUTOR(ES)
Slifka, Mark K
FONTE
BioMed Central
RESUMO
Eradication of the smallpox virus through extensive global vaccination efforts has resulted in one of the most important breakthroughs in medical history, saving countless lives from the severe morbidity and mortality that is associated with this disease. Although smallpox is now extinct in nature, laboratory stocks of this virus still remain and the subject of smallpox vaccination has gained renewed attention due to the potential risk that smallpox may be used as a biological weapon by terrorists or rogue states. Despite having the longest history of any modern vaccine, there is still much to be learned about smallpox vaccination and the correlates of protection remain to be formally defined. This Commentary will discuss the strengths and weaknesses of traditional smallpox vaccination in comparison with immunization using modified vaccinia virus Ankura (MVA), a non-replicating virus with a strong safety record but weakened immunogenicity.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=554756Documentos Relacionados
- Inoculation and vaccination: smallpox, cowpox and vaccinia.
- Smallpox Vaccination: ABO and Rhesus Blood Groups
- Logistics of community smallpox control through contact tracing and ring vaccination: a stochastic network model
- Risks of serious complications and death from smallpox vaccination: A systematic review of the United States experience, 1963–1968
- Vaccination: refuting the refusals
